Prediction of methotrexate intolerance in juvenile idiopathic arthritis: a prospective, observational cohort study.

ABSTRACT:

Background

Methotrexate (MTX) is an effective and safe drug in the treatment of juvenile idiopathic arthritis (JIA). Despite its safety, MTX-related gastrointestinal adverse effects before and after MTX administration, termed MTX intolerance, occur frequently, leading to non-compliance and potentially premature MTX termination. The aim of this study was to construct a risk model to predict MTX intolerance.

Methods

In a prospective JIA cohort, clinical variables and single nucleotide polymorphisms were determined at MTX start. The Methotrexate Intolerance Severity Score was employed to measure MTX intolerance in the first year of treatment. MTX intolerance was most prevalent at 6 or 12 months after MTX start, which was defined as the outcome for the prediction model. The mode

SUBMITTER: van Dijkhuizen EH 

PROVIDER: S-EPMC4349799 | biostudies-literature | 2015

REPOSITORIES: biostudies-literature